Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 24:5:368.
doi: 10.1186/s40064-016-1998-7. eCollection 2016.

Clinical significance of serum CA125 in diffuse malignant mesothelioma

Xu Cheng  1 , Hong-Feng Gou  2 , Ji-Yan Liu  2 , De-Yun Luo  2 , Meng Qiu  2
Affiliations

Clinical significance of serum CA125 in diffuse malignant mesothelioma

Xu Cheng et al. Springerplus. .

Abstract

Background: Malignant mesothelioma (MM) is a rare and fatal neoplasm. For diffuse malignant mesothelioma (DMM) patients that were not suitable for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, systemic chemotherapy is the main treatment. There are no convenient tumor markers to predict the efficacy of treatment and disease progression. This study aimed to evaluate serum CA125 level as a biochemical marker of response to therapy and prognosis in patients with DMM.

Methods: A retrospective study was performed in a single medical institution from April 2008 to April 2014. Overall survival (OS) and prognostic factors were assessed.

Results: Forty-one patients were included with a median age of 53 years. The median OS of all patients was 10 months. Patients with baseline CA125 > 280 U/ml had worse OS compared with the patients that baseline CA125 ≤ 280 U/ml. Baseline level of CA125, stage of disease, primary tumor location and systemic chemotherapy were independent prognostic factors associated with OS. In patients who received systemic chemotherapy, the decline in serum CA125 was associated with favorable OS and objective response according to modified Response Evaluation Criteria in Solid Tumors criteria.

Conclusions: The baseline level of serum CA125, accompanied with stage of disease, primary tumor location and systemic chemotherapy, could be regarded as independent prognostic factors for DMM patients. Otherwise, the change in serum CA125 can predict OS and response to systemic chemotherapy.

Keywords: CA-125 antigen; Drug therapy; Mesothelioma; Prognosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival of all 41 patients. The median overall survival (OS) for 41 patients was 10 months
Fig. 2
Fig. 2
The survival of DMPlM patients and DMPeM patients subgroups. The median survival (OS) of DMPlM patients was 6 months. The median OS of DMPeM patients subgroup was longer than 24 months, P = 0.003
Fig. 3
Fig. 3
The best stratified level of baseline serum CA125 for predict DMM patients outcome. The best stratified level of baseline serum CA125 for predict DMM patients outcome was 280 U/ml (eight times of upper normal limit), P = 0.045
Fig. 4
Fig. 4
The association between change in serum CA125 and OS for patients who had received systemic chemotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alexander HR, Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779–786. doi: 10.1016/j.surg.2013.01.001. - DOI - PMC - PubMed
    1. Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14(2):500–508. doi: 10.1245/s10434-006-9192-8. - DOI - PubMed
    1. Baratti D, Kusamura S, Deraco M. Circulating CA125 and diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2009;35(11):1198–1199. doi: 10.1016/j.ejso.2009.04.007. - DOI - PubMed
    1. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257–260. doi: 10.1093/annonc/mdh059. - DOI - PubMed
    1. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Jr, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23(5):815–822. doi: 10.1097/IGC.0b013e31828f7a24. - DOI - PMC - PubMed